Screening with a PSA test has a small impact on prostate cancer deaths but leads to overdiagnosis

The largest study to date investigating a single invitation to a PSA blood test* to screen for prostate cancer has found it had a small impact on reducing deaths, but also led to overdiagnosis and missed early detection of some aggressive cancers. The CAP trial, published in the Journal of the American Medical Association (JAMA) and carried out by researchers from the universities of Bristol, Oxford and Cambridge, involved over 400,000 men aged 50-69. Just under half received a single invitation for a PSA test as part of the trial.
Source: University of Bristol news - Category: Universities & Medical Training Tags: Health, Research, International; Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School, Institutes, Institutes, Bristol Population Health Science Institute; Press Release Source Type: news